Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model

Cornea

Volumn 26, Issue 1, 2007, Pages 84-89

  Lekhanont, Kaevalin ^a   Leyngold, Ilya M ^a   Suwan Apichon, Olan ^b   Rangsin, Ram ^c   Chuck, Roy S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KHON KAEN UNIVERSITY   (Thailand)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

Botulinum toxin; Dry eye; Mouse model; Treatment

Indexed keywords

ARTIFICIAL TEAR; BOTULINUM TOXIN B; CYCLOSPORIN A; FLUOROMETHOLONE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORNEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; EYELID REFLEX; FEMALE; KERATOCONJUNCTIVITIS SICCA; LACRIMAL GLAND; LACRIMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; BLINKING; BOTULINUM TOXINS; CORNEA; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCENT DYES; FLUOROMETHOLONE; KERATOCONJUNCTIVITIS SICCA; MICE; MICE, INBRED CBA; OPHTHALMIC SOLUTIONS; SODIUM CHLORIDE; STAINING AND LABELING; TEARS;

EID: 33846023356     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000240079.24583.a1     Document Type: Article

References (37)

1. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221-232.
2. Brignole F, Pisella PJ, Goldschild M, et al. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41:1356-1363.
3. Pflugfelder SC. Anti-inflammatory therapy of dry eye. The Ocular Surface. 2003;1:31-36.
4. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. Ophthalmology. 1999;106:811-816.
5. Gunduz K, Ozdemir O. Topical cyclosporine treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome. Acta Ophthalmol (Copenh). 1994;72:438-442.
6. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-639.
7. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119-125.
8. Halestrap AP, Connern CP, Griffiths EJ, et al. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem. 1997;174:167-172.
9. Brignole F, Pisella PJ, Desaint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A. Invest Ophthalmol Vis Sci. 2001;42:90-95.
10. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
11. Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology. 2004;11:783-791.
12. Goto E, Shimazaki J, Monden Y, et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology. 2002;109:2030-2035.
13. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632-638.
14. Fujihara T, Nagano T, Nakamura M, et al. Establishment of a rabbit short-term dry eye model. J Ocul Pharmacol Ther. 1995;11:503-508.
15. Maitchouk DY, Beuerman RW, Ohta T, et al. Tear production after unilateral removal of the main lacrimal gland in squirrel monkeys. Arch Ophthalmol. 2000;118:246-252.
16. Nakamura S, Shibuya M, Nakashima H, et al. D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board. Invest Ophthalmol Vis Sci. 2005;46:2379-2387.
17. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53:3-9.
18. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529-1534.
19. Horwath-Winter J, Bergloeff J, Floegel I, et al. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol. 2003;87:54-56.
20. Matarasso SL. Decreased tear expression with an abnormal Schirmer's test following botulinum toxin type A for the treatment of lateral canthal rhytides. Dermatol Surg. 2002;28:149-152.
21. Kyrmizakis DE, Pangalos A, Papadakis CE, et al. The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes. J Oral Maxillofac Surg. 2004;62:840-844.
22. Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 2003;29:7-13.
23. Flynn TC, Clark RE. Botulinum toxin B (Myobloc) versus botulinum toxin A (Botox) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519-522.
24. Suwan-Apichon O, Rizen M, Rangsin R, et al. Botulinum toxin B induced mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2006;47:133-139.
25. Montoya FJ, Riddell CE, Caesar R, et al. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye. 2002;16:705-709.
26. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45(Suppl 2):S211-S220.
27. Dressler D. Botulinum toxin mechanisms of action. Suppl Clin Neurophysiol. 2004;57:159-166.
28. Smith RS, Sundberg JP, John SWM. The anterior segment and ocular adnexae. In: Smith RS, John SWM, Nishina PM, Sundberg JP, eds. Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biomethods. Boca Raton, FL; CRC Press; 2002:3-24.
29. Nagelhout TJ, Gamache DA, Roberts L, et al. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J Ocul Pharmacol Ther. 2005;21:139-148.
30. Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol. 2003;136:593-602.
31. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-457.
32. Stevenson D, Tauber J, Reis BL. Cyclosporine A phase 2 study group. Efficacy and safety of cyclosporine: a ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease a dose-ranging, randomized trial. Ophthalmology. 2000;107:967-974.
33. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489-1496.
34. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492-496.
35. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004;45:4302-4311.
36. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol. 2005;166:61-71.
37. Dursun D, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8-13.